<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01989780</url>
  </required_header>
  <id_info>
    <org_study_id>JBCRG-M04</org_study_id>
    <nct_id>NCT01989780</nct_id>
  </id_info>
  <brief_title>Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer</brief_title>
  <acronym>BOOSTER</acronym>
  <official_title>Bevacizumab Plus Paclitaxel Optimization Study With Interventional Maintenance Endocrine Therapy in Advanced or Metastatic ER-positive HER2-negative Breast Cancer -BOOSTER Trial, a Multicenter Randomized Phase II Study-</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Japan Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chugai Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Japan Breast Cancer Research Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate optimal usage of bevacizumab to compare which is better, continuing bevacizumab&#xD;
      and paclitaxel or switching to hormonal maintenance therapy followed by&#xD;
      bevacizumab+paclitaxel after induction therapy of bevacizumab+paclitaxel.&#xD;
&#xD;
      To examine biomarkers such as monitoring markers of study treatment as exploratory analysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multicenter, randomized Phase II study of patients with advanced or metastatic estrogen&#xD;
      receptor-positive human epidermal receptor type 2-negative breast cancer aims to compare two&#xD;
      treatment strategies following induction therapy with 4-6 cycles of the combined use of&#xD;
      weekly paclitaxel (wPTX) and bevacizumab (BV). In arm A, wPTX+BV is continued, while in arm&#xD;
      B, wPTX is switched to maintenance endocrine therapy (hormone+BV) until disease progression,&#xD;
      followed by wPTX+BV re-induction. The primary endpoint is time to failure of strategy, which&#xD;
      is the time from randomization to a qualifying event (addition of a new agent not in the&#xD;
      primary regimen, progressive disease during or after planned therapy, or death).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to failure of strategy (TFS)</measure>
    <time_frame>3.5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>2y Overall Survival rate</measure>
    <time_frame>3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3.5years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival(PFS)</measure>
    <time_frame>3.5years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOL</measure>
    <time_frame>3.5years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker(IMPACT assay Chips, whole blood, tumor tissue, Serum)</measure>
    <time_frame>3.5years</time_frame>
    <description>vascular endothelial growth factor(VEGF)-A, VEGFR-2, VEGF-C, platelet derived growth factor(PDGF)-C, Soluble fms-like tyrosine kinase-1, VEGFR-3, Interleukin(IL)-8, Basic Fibroblast Growth Factor(FGFb), placental growth factor(PLGF), E-Selectin, intercellular adhesion molecule(ICAM)-1, neuropilin of Tumor tissue, single nucleotide polymorphism(SNP):VEGFR-1 and VEGF of whole blood DNA, angiotensin(ANG) and Apelin of serum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety(Collection of adverse events)</measure>
    <time_frame>3.5years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>weekly paclitaxel + bevacizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>weekly paclitaxel + bevacizumab followed by hormone therapy(Treatment of physician's choice)* + bevacizumab then back to weekly paclitaxel + bevacizumab&#xD;
* Letrozole, Anastrozole, Exemestane, Fulvestrant, Goserelin, leuprorelin or LHRH Analogs + Aromatase inhibitors.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Femara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole</intervention_name>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Arimidex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exemestane</intervention_name>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Aromasin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Faslodex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin</intervention_name>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Zoladex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leuprorelin</intervention_name>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Leuplin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LHRH Analogs + Aromatase inhibitors</intervention_name>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Zoladex or Leuplin + Femara or Arimidex or Aromasin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed adenocarcinoma of the breast&#xD;
&#xD;
          2. Female aged 20-75 years old at getting informed consent&#xD;
&#xD;
          3. HER2 negative disease (IHC 0/1+ or 2+ with FISH negative)&#xD;
&#xD;
          4. Documented estrogen receptor (ER) positive (&gt;=1% by IHC)&#xD;
&#xD;
          5. Inoperative locally advanced or metastatic breast cancer at enrolment&#xD;
&#xD;
          6. Performance status (ECOG): 0-1 at enrolment&#xD;
&#xD;
          7. Life expectancy of at least 3 months from enrolment&#xD;
&#xD;
          8. No prior systemic therapy for recurrent breast cancer (excluding hormone therapy)&#xD;
&#xD;
          9. No prior neo and/or adjuvant chemotherapy with taxane or adjuvant setting with a&#xD;
             disease-free interval from completion of the taxane treatment to metastatic diagnosis&#xD;
             of &gt;= 12 months&#xD;
&#xD;
         10. Patients with measurable lesion regarding with Response Evaluation Criteria in Solid&#xD;
             Tumors(RECIST) criteria or who have evaluable lesion&#xD;
&#xD;
         11. Patients with only bone lesion will be acceptable if the osteolytic lesion has a&#xD;
             measurable soft tissue component by MRI or CT&#xD;
&#xD;
         12. No influence on protocol treatment is considered in case prior therapy or examination.&#xD;
&#xD;
         13. Adequate following organ function within 2 weeks before starting treatment. The latest&#xD;
             examination results should be adopted and blood transfusion or treatment of&#xD;
             hematopoietic factor drugs is not allowed 2 weeks before examination.&#xD;
&#xD;
               -  Absolute neutrophil count &gt;= 1500 /mm3 or white blood cell(WBC) count &gt;= 3000&#xD;
                  /mm3&#xD;
&#xD;
               -  Platelets &gt;=10 x 10000 /mm3&#xD;
&#xD;
               -  Hb &gt;= 9 g/dL&#xD;
&#xD;
               -  Total bilirubin &lt;= 1.5 mg/dL&#xD;
&#xD;
               -  aspartate aminotransferase(AST) and alanine aminotransferase(ALT) &lt;= 100&#xD;
                  international unit(IU)/L&#xD;
&#xD;
               -  Serum creatinine &lt;= 1.5 mg/dL&#xD;
&#xD;
               -  Urine dipstick for proteinuria &lt;= 1+&#xD;
&#xD;
         14. Written informed consent signed by patients before completing any treatment related&#xD;
             procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior therapy with bevacizumab&#xD;
&#xD;
          2. Active infection requiring intrvenous antibiotics at enrollment or infection with&#xD;
             active HBV and/or HCV.&#xD;
&#xD;
          3. Pregnancy, lactetion or in case of potentialy pregnancy women Not mind contraception&#xD;
             in trial period.&#xD;
&#xD;
          4. Known hypersensitivity to bevacizumab or paclitaxel&#xD;
&#xD;
          5. History of hemoptysis (&gt;= 2.5mL of bright red blood per episord).&#xD;
&#xD;
          6. Use of disulfiram,cyanamide, carmofur or procarbazine Hydrochloride&#xD;
&#xD;
          7. Patients with CNS metastases (except for not symptomatic)&#xD;
&#xD;
          8. Persistent Grade &gt;= 2 sensory neuropathy at enrollment&#xD;
&#xD;
          9. Grade 3 &gt;= hypertension (&gt;= 2 use of antihypertensive drug)&#xD;
&#xD;
         10. Evidence with arterial thromboembolism (Cerebral infarction, Myocardial infarction) or&#xD;
             history within 1 year prior to enrollment.&#xD;
&#xD;
         11. Evidence withvenous thromboembolism (deep vein thrombosis, pulmonary embolism) or&#xD;
             history within 1 year prior to enrollment.&#xD;
&#xD;
         12. History of GI perforation and/or serious abdominal fistula within 1 year prior to&#xD;
             enrollment&#xD;
&#xD;
         13. Cases that the investigator judged as inappropriate as the subject of this clinical&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masakazu Toi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyoto University, Graduate School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shigehira Saji, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fukushima Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Japan Breast Cancer Research Group</name>
      <address>
        <city>Chuo-ku, Nihonbashi, Koami-cho</city>
        <state>Tokyo</state>
        <zip>1030016</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>November 4, 2013</study_first_submitted>
  <study_first_submitted_qc>November 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2013</study_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

